July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Silicone oil for radiation attenuation in the treatment of small uveal melanoma
Author Affiliations & Notes
  • Nicholas Iafe
    Stein Eye Institute, SANTA MONICA, California, United States
  • David Xu
    Stein Eye Institute, SANTA MONICA, California, United States
  • Daniel Su
    Stein Eye Institute, SANTA MONICA, California, United States
  • Tara McCannel
    Stein Eye Institute, SANTA MONICA, California, United States
  • Footnotes
    Commercial Relationships   Nicholas Iafe, None; David Xu, None; Daniel Su, None; Tara McCannel, Impact Genetics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4297. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicholas Iafe, David Xu, Daniel Su, Tara McCannel; Silicone oil for radiation attenuation in the treatment of small uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4297.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Radiation retinopathy is a frequent cause of vision loss after iodine-125 (125I) plaque brachytherapy in the treatment of uveal melanoma. Vitrectomy with silicone oil (SO) 1000 centistokes placement has been shown to decrease radiation retinopathy in large uveal melanoma due to radiation attenuation of SO. We analyzed the outcome of 125I brachytherapy with vitrectomy and SO placement in the treatment of small uveal melanoma with apical height <3 mm.

Methods : This was a retrospective case-control study including 36 patients treated with 125I plaque brachytherapy and vitrectomy with SO placement and 29 control patients treated with 125I plaque alone. Patients received routine post-op ocular and systemic surveillance including dilated fundus exam, B-scan, and Optos widefield fluorescein angiography to assess for radiation retinopathy at 6, 12, 24, and 36 months. Radiation retinopathy severity was graded based on evidence of foveal and peripheral leakage, non-perfusion, and retinal neovascularization using a validated 4-point scale. The impact of SO placement on radiation retinopathy, visual acuity and metastasis was reviewed at 3 years post plaque treatment.

Results : Twenty-seven case patients (mean age 61, 59% female) and 15 control patients (mean age 61, 40% female) were available for analysis at 3 years post plaque. Mean tumor height was 2.23 mm in controls and 2.43 mm in cases (P=0.08). The final logMAR VA was 0.86 in cases and 0.38 in controls (P = 0.03); the change from pre-treatment to final logMAR was 0.76 in cases and 0.2 in controls (P = 0.006). The proportion of eyes with each grade of retinopathy was similar between groups (P = 0.99). All 42 eyes achieved local tumor control without distant metastasis.

Conclusions : 125I brachytherapy for small uveal melanoma is effective in achieving local tumor control. In contrast to treatment of large uveal melanoma, combining brachytherapy with vitrectomy and SO for radiation attenuation did not significantly improve vision over the use of plaque alone. SO placement for 125I radiation attenuation in small tumors may not yield additional visual or angiographic benefit at 3 years post brachytherapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Optos widefield FA examples of radiation retinopathy severity grades: 0=none, 1=foveal leakage, 2=peripheral leakage, 3=non-perfusion, 4=neovascularization.

Optos widefield FA examples of radiation retinopathy severity grades: 0=none, 1=foveal leakage, 2=peripheral leakage, 3=non-perfusion, 4=neovascularization.

 

Histogram comparing proportion of cases and controls with each grade of radiation retinopathy at 3 years.

Histogram comparing proportion of cases and controls with each grade of radiation retinopathy at 3 years.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×